Highly immunogenic trimethyl chitosan-based delivery system for intranasal lipopeptide vaccines against group A streptococcus

Marasini, Nirmal, Ghaffar, Khairunnisa Abdul, Giddam, Ashwini Kumar, Batzloff, Michael R., Good, Michael F., Skwarczynski, Mariusz and Toth, Istvan (2016) Highly immunogenic trimethyl chitosan-based delivery system for intranasal lipopeptide vaccines against group A streptococcus. Current Drug Delivery, 13 8: . doi:10.2174/1567201813666160721141322


Author Marasini, Nirmal
Ghaffar, Khairunnisa Abdul
Giddam, Ashwini Kumar
Batzloff, Michael R.
Good, Michael F.
Skwarczynski, Mariusz
Toth, Istvan
Title Highly immunogenic trimethyl chitosan-based delivery system for intranasal lipopeptide vaccines against group A streptococcus
Journal name Current Drug Delivery   Check publisher's open access policy
ISSN 1875-5704
1567-2018
Publication date 2016-07-21
Year available 2016
Sub-type Article (original research)
DOI 10.2174/1567201813666160721141322
Open Access Status Not Open Access
Volume 13
Issue 8
Total pages 1
Place of publication Bussum, Netherlands
Publisher Bentham Science Publishers
Collection year 2017
Language eng
Abstract Group A streptococcus (GAS) infections can led to a large variety of diseases in humans including the most common acute pharyngitis. If untreated, GAS infections lead to life- threatening conditions such as rheumatic heart diseases and post-streptococcal glomerulonephritis. GAS primarily colonises the mucosal region of the upper respiratory tract, slowly leading to systemic infections. Thus, GAS-specific antibody responses are desirable at mucosal sites for early prevention against GAS colonisation. Although several GAS vaccines are currently in clinical trials, these vaccines aim to stimulate systemic immunity, not mucosal immunity, thus will not protect against colonization. Herein, we developed a potent nanoliposomes-based delivery system for mucosally active lipid core peptide (LCP)-based vaccines. Trimethyl chitosan (TMC)-coated liposomes that bore a B-cell epitope derived from GAS M-protein, stimulated potent epitope-specific mucosal and systemic antibody titres after only one boost following intranasal immunisation in Swiss outbred mice. The immune responses were durable even at day 139 post-primary immunisation. The enhanced vaccine efficacy, lowered dose, and simple and cost-effective process of producing the coated nanoliposomes should be particularly useful in developing potent peptide-based vaccines to prevent infections at the mucosal sites.
Keyword Lipopeptides
Peptide vaccines
Nasal delivery
Chitosan
Liposomes
Group A streptococcus
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
School of Chemistry and Molecular Biosciences
School of Pharmacy Publications
 
Versions
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Fri, 29 Jul 2016, 10:16:37 EST by Mrs Louise Nimwegen on behalf of School of Chemistry & Molecular Biosciences